The Danish drugmaker’s offer, whose value couldn’t be learned, comes in response to Pfizer bumping its bid for Metsera Wednesday to as much as $86.20 a share including milestone payments, people familiar with the matter said. Pfizer’s revised bid matched Novo’s earlier proposal.
The bidding war is expected to conclude in a matter of days, according to the people. Metsera’s decision will likely come down to which party can pay more.
“As of today, our bid is ...